Ikena Oncology, Inc. (IKNA)

NASDAQ: IKNA · IEX Real-Time Price · USD
1.510
-0.010 (-0.66%)
Feb 27, 2024, 12:44 PM EST - Market open
-0.66%
Market Cap 73.35M
Revenue (ttm) 13.95M
Net Income (ttm) -62.77M
Shares Out 48.26M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 426,190
Open 1.540
Previous Close 1.520
Day's Range 1.430 - 1.560
52-Week Range 1.020 - 7.640
Beta 0.27
Analysts Strong Buy
Price Target 13.50 (+794.04%)
Earnings Date Mar 12, 2024

About IKNA

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metasta... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol IKNA
Full Company Profile

Financial Performance

In 2022, Ikena Oncology's revenue was $15.62 million, a decrease of -49.59% compared to the previous year's $30.99 million. Losses were -$68.77 million, 101.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 794.04% from the latest price.

Price Target
$13.5
(794.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announc...

4 hours ago - GlobeNewsWire

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise

5 days ago - GlobeNewsWire

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core ta...

5 weeks ago - GlobeNewsWire

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptio...

3 months ago - GlobeNewsWire

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announc...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA)

NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of fiduciary duty. To obtai...

5 months ago - PRNewsWire

Ikena Oncology to Participate in September 2023 Investor Conferences

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announ...

6 months ago - GlobeNewsWire

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by y...

7 months ago - GlobeNewsWire

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif.,...

7 months ago - GlobeNewsWire

Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that mana...

9 months ago - GlobeNewsWire

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date

10 months ago - GlobeNewsWire

Ikena Oncology Announces $40 Million Underwritten Offering

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced toda...

10 months ago - GlobeNewsWire

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that ma...

11 months ago - GlobeNewsWire

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930's differentiated paralog selectivity and robust repressor activity in comp...

11 months ago - GlobeNewsWire

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025

1 year ago - GlobeNewsWire

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that th...

1 year ago - GlobeNewsWire

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that th...

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that man...

1 year ago - GlobeNewsWire

Ikena Oncology Appoints Owen Hughes as Board Chair

Owen Hughes joins Ikena Board as independent director with operational and public company experience

1 year ago - GlobeNewsWire

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that man...

1 year ago - GlobeNewsWire

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma

1 year ago - GlobeNewsWire

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab

1 year ago - GlobeNewsWire

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab

1 year ago - GlobeNewsWire

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a poster...

1 year ago - GlobeNewsWire